Home LiteratureArticle Details
PMID: 21680779 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

Cancer research ·Vol. 71 ·No. 15 ·2011-08-01 ·Pages 5101-10

Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, Carson WE

Abstract

Our group and others have determined that immune effector cells from patients with advanced cancers exhibit reduced activation of IFN signaling pathways. We hypothesized that increases in immune regulatory cells termed myeloid-derived suppressor cells (MDSC) could interfere with the host immune response to tumors by inhibiting immune cell responsiveness to IFNs. The C26 murine adenocarcinoma model was employed to study immune function in advanced malignancy. C26-bearing mice had significantly elevated levels of GR1(+)CD11b(+) MDSC as compared with control mice, and splenocytes from tumor-bearing mice exhibited reduced phosphorylation of STAT1 (P-STAT1) on Tyr(701) in response to IFN-α or IFN-γ. This inhibition was seen in splenic CD4(+) and CD8(+) T cells as well as natural killer cells. In vitro coculture experiments revealed that MDSC inhibited the IFN responsiveness of splenocytes from normal mice. Treatment of C26-bearing mice with gemcitabine or an anti-GR1 antibody led to depletion of MDSC and restored splenocyte IFN responsiveness. Spleens from C26-bearing animals displayed elevated levels of iNOS protein and nitric oxide. In vitro treatment of splenocytes with a nitric oxide donor led to a decreased STAT1 IFN response. The elevation in nitric oxide in C26-bearing mice was associated with increased levels of nitration on STAT1. Finally, splenocytes from iNOS knockout mice bearing C26 tumors exhibited a significantly elevated IFN response as compared with control C26 tumor-bearing mice. These data suggest that nitric oxide produced by MDSC can lead to reduced IFN responsiveness in immune cells.

MeSH Terms
Adenocarcinoma/drug therapy,immunology,pathology Animals CD11b Antigen/analysis Coculture Techniques Colonic Neoplasms/drug therapy,immunology,pathology Deoxycytidine/analogs & derivatives,therapeutic use Female Interferon Type I/pharmacology Interferon-gamma/pharmacology Interferons/antagonists & inhibitors Male Mice Mice, Inbred BALB C Mice, Inbred DBA Mice, Knockout Myeloid Cells/physiology Neoplasm Proteins/metabolism Nitric Oxide/metabolism Nitric Oxide Donors/pharmacology Nitric Oxide Synthase Type II/analysis,deficiency Phosphorylation Protein Processing, Post-Translational Receptors, Cell Surface/analysis,antagonists & inhibitors,immunology Receptors, Interferon Recombinant Proteins STAT1 Transcription Factor/metabolism Spleen/enzymology,pathology Tumor Escape/immunology
Chemicals
CD11b Antigen Interferon Type I Neoplasm Proteins Nitric Oxide Donors Receptors, Cell Surface Receptors, Interferon Recombinant Proteins STAT1 Transcription Factor Stat1 protein, mouse granulocyte receptor 1, mouse interferon gamma receptor Deoxycytidine Nitric Oxide Interferon-gamma Interferons gemcitabine Nitric Oxide Synthase Type II Nos2 protein, mouse
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Mundy-Bosse Bethany L
Department of Integrated Biomedical Sciences, the Ohio State University, Columbus, OH, USA.
Lesinski Gregory B
Jaime-Ramirez Alena C
Benninger Kristen
Khan Mahmood
Kuppusamy Periannan
Guenterberg Kristan
Kondadasula Sri Vidya
Chaudhury Abhik Ray
La Perle Krista M
Kreiner Melanie
Young Gregory
Guttridge Denis C
Carson William E
References (40)
40 references, click to expand
  1. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
    Expert Opin Biol Ther. 2007 Aug;7(8):1257-66 PMID: 17696823
  2. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
    Cancer Res. 2007 Oct 15;67(20):10019-26 PMID: 17942936
  3. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  4. Regulation of immune responses by L-arginine metabolism.
    Nat Rev Immunol. 2005 Aug;5(8):641-54 PMID: 16056256
  5. Tumor escape mechanism governed by myeloid-derived suppressor cells.
    Cancer Res. 2008 Apr 15;68(8):2561-3 PMID: 18413722
  6. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
    J Immunol. 2011 Mar 15;186(6):3401-9 PMID: 21321106
  7. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
    J Clin Oncol. 2005 Dec 1;23(34):8835-44 PMID: 16314644
  8. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s PMID: 17255300
  9. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.
    J Immunol. 2009 May 1;182(9):5693-701 PMID: 19380816
  10. Myeloid-derived suppressor cells: linking inflammation and cancer.
    J Immunol. 2009 Apr 15;182(8):4499-506 PMID: 19342621
  11. Impaired response to interferon-gamma in activated macrophages due to tyrosine nitration of STAT1 by endogenous nitric oxide.
    Br J Pharmacol. 2001 Jan;132(2):419-26 PMID: 11159690
  12. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
    Cancer Res. 2009 Feb 15;69(4):1553-60 PMID: 19201693
  13. Modulators of arginine metabolism support cancer immunosurveillance.
    BMC Immunol. 2009 Jan 09;10:1 PMID: 19134173
  14. Impaired interferon signaling is a common immune defect in human cancer.
    Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9010-5 PMID: 19451644
  15. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death.
    J Immunol. 1999 Mar 15;162(6):3356-66 PMID: 10092790
  16. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
    Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 PMID: 9636188
  17. A critical function for type I interferons in cancer immunoediting.
    Nat Immunol. 2005 Jul;6(7):722-9 PMID: 15951814
  18. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
    J Immunol. 2002 Jan 15;168(2):689-95 PMID: 11777962
  19. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.
    Immunol Rev. 2008 Apr;222:180-91 PMID: 18364002
  20. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  21. Interferons, immunity and cancer immunoediting.
    Nat Rev Immunol. 2006 Nov;6(11):836-48 PMID: 17063185
  22. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
    J Immunol. 2007 Apr 15;178(8):4832-45 PMID: 17404264
  23. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    J Immunol. 2009 Feb 15;182(4):2492-501 PMID: 19201905
  24. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Clin Cancer Res. 2005 Sep 15;11(18):6713-21 PMID: 16166452
  25. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Int Immunopharmacol. 2009 Jul;9(7-8):900-9 PMID: 19336265
  26. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.
    J Immunol. 2010 Mar 15;184(6):3106-16 PMID: 20142361
  27. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
    J Clin Invest. 2003 Jul;112(2):170-80 PMID: 12865406
  28. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.
    J Immunol. 1992 Jun 1;148(11):3674-8 PMID: 1534101
  29. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
    J Natl Cancer Inst. 2004 Sep 1;96(17):1331-42 PMID: 15339971
  30. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
    Cancer Res. 2010 Jan 1;70(1):68-77 PMID: 20028852
  31. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
    J Immunol. 2005 Jan 15;174(2):636-45 PMID: 15634881
  32. Interferon-alpha in tumor immunity and immunotherapy.
    Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 PMID: 11900988
  33. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
    Clin Cancer Res. 2007 Sep 1;13(17):5010-9 PMID: 17785551
  34. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
    J Immunol. 1998 Nov 15;161(10):5313-20 PMID: 9820504
  35. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
    PLoS Med. 2007 May;4(5):e176 PMID: 17488182
  36. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
    J Clin Invest. 2006 Oct;116(10):2777-90 PMID: 17016559
  37. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
    Blood. 2000 Dec 1;96(12):3838-46 PMID: 11090068
  38. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Cancer Res. 2007 Aug 1;67(15):7477-86 PMID: 17671218
  39. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.
    Clin Cancer Res. 2009 Mar 15;15(6):2123-9 PMID: 19276257
  40. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes.
    J Immunol. 2008 Sep 1;181(5):3291-300 PMID: 18714001
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
1538-7445
Published
2011-08-01
Epub
2011-00-16
Pages
5101-10
Language
English
Region
United States
NLM ID
2984705R
PMCID
PMC3148319
Subset
IM
Grants
NCI NIH HHS · P01 CA95426 · United States
NCI NIH HHS · K24 CA093670 · United States
NCI NIH HHS · K24-CA93670 · United States
NCI NIH HHS · R21 CA084402-02S1 · United States
NCI NIH HHS · CA84402 · United States
NCI NIH HHS · T32 CA009338-33 · United States
NCI NIH HHS · P01 CA095426 · United States
NCI NIH HHS · K22 CA134551 · United States
NCI NIH HHS · P30 CA134551 · United States
NCI NIH HHS · K24 CA093670-10 · United States
NCI NIH HHS · T32 CA009338 · United States
NIGMS NIH HHS · T32 GM068412-05 · United States
NCI NIH HHS · K22CA134551 · United States
NCI NIH HHS · K22 CA134551-03 · United States
NCI NIH HHS · P01 CA095426-10 · United States
NIGMS NIH HHS · T32 GM068412 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]